<DOC>
	<DOCNO>NCT00203177</DOCNO>
	<brief_summary>Study look effectiveness , tolerability safety two dos Rasagiline ( 0.5 mg 1mg ) advance Parkinson 's Disease ( PD ) Patients treat Levodopa/Carbidopa therapy .</brief_summary>
	<brief_title>Rasagiline Advanced Parkinson 's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients must complete Week 26 visit TVP 1012/133 ( Visit 06 ) accordance protocol . Women must postmenopausal , surgically sterile , use adequate birth control method . Women childbearing potential must negative pregnancy test Baseline/Month 0 . Patients must willing able give inform consent . Serious severe , test drugrelated ( probable definite ) adverse reaction study TVP 1012/133 . Premature discontinuation study TVP 1012/133 reason . A clinically significant unstable medical surgical condition would preclude safe complete study participation . Such condition may include cardiovascular , pulmonary hepatic , renal , metabolic disease malignancy determine medical history , physical exam , skin evaluation , laboratory test , chest xray , ECG .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>